Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes: A Randomized Controlled Trial

ABSTRACT: Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes: A Randomized Controlled Trial

PROVIDER: PRJNA926663 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23195426.fastq.gz	Fastqsanger.gz
	SRR23195427.fastq.gz	Fastqsanger.gz
	SRR23195428.fastq.gz	Fastqsanger.gz
	SRR23195429.fastq.gz	Fastqsanger.gz
	SRR23195430.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 65

Similar Datasets

Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes: A Randomized Controlled Trial

Project description:In the current study we evaluated the effect of glimepiride, liraglutide on the expression of the circulating miRNAs. Univariate analyses show that treatment with glimepiride altered expression of three miRNAs in patient serum, miR-206, miR-182-5p, and miR-766-3p. Both miR-182-5p and miR-766-3p were also picked up among the top contributing miRNAs with penalized regularised logistic regressions (Lasso). The highest-ranked miRNAs with respect to Lasso coefficients were miR-3960, miR-31-5p, miR-3613-3p, and miR-378a-3p. Liraglutide treatment did not significantly influence levels of circulating miRNAs. Present study indicates that glucose-lowering drugs differently affect the expression of circulating miRNAs in serum in individuals with T2DM. More studies are required to investigate possible mechanisms by which glimepiride is affecting the expression of circulating miRNAs.

2023-01-26 | GSE223538 | GEO

Genes altered by miR-766-5p in two cancer cell lines

Project description:To identify genes affected by miR-766-5p overexpression, we transfected with 10nmol of miR-766-5p or miR-negative control (NC) in HCT116-/-, or MIAPaCa2 cells. After 2 days, RNA was extracted, and then expression analysis was performed using agilent microarray.

2021-07-25 | GSE180688 | GEO

Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial.

Project description:BackgruoundDiabetes is a chronic disease with several long-term complications. Several glucose-lowering drugs are used to treat type 2 diabetes mellitus (T2DM), e.g., glimepiride and liraglutide, in which both having different modes of action. Circulating microRNAs (miRNAs) are suggested as potential biomarkers that are associated with the disease development and the effects of the treatment. In the current study we evaluated the effect of glimepiride, liraglutide on the expression of the circulating miRNAs.MethodsThe present study is a post hoc trial from a previously randomized control trial comparing liraglutide versus glimepiride both in combination with metformin in subjects with T2DM, and subclinical heart failure. miRNAs were determined in the subjects' serum samples with next generation sequencing. Expression patterns of the circulating miRNAs were analyzed using bioinformatic univariate and multivariate analyses (clinical trial registration: NCT01425580).ResultsUnivariate analyses show that treatment with glimepiride altered expression of three miRNAs in patient serum, miR-206, miR-182-5p, and miR-766-3p. Both miR-182-5p and miR-766-3p were also picked up among the top contributing miRNAs with penalized regularised logistic regressions (Lasso). The highest-ranked miRNAs with respect to Lasso coefficients were miR-3960, miR-31-5p, miR-3613-3p, and miR-378a-3p. Liraglutide treatment did not significantly influence levels of circulating miRNAs.ConclusionPresent study indicates that glucose-lowering drugs differently affect the expression of circulating miRNAs in serum in individuals with T2DM. More studies are required to investigate possible mechanisms by which glimepiride is affecting the expression of circulating miRNAs.

| S-EPMC10555542 | biostudies-literature

miR-206/133b knock-out

Project description:miR-206/133b knock-out WT vs. mutant M.soleus

2014-12-17 | E-MTAB-2439 | biostudies-arrayexpress

miR-182 inhibition in AKI

Project description:gene expression modification after miR-182 inhibition, day 2 and day 7 after ischemic reperfusion injury

2017-06-30 | GSE69803 | GEO

miR-34a, miR-122, miR-206 and miR-210 targets identification

Project description:To identify putative novel specific targets of miR-34a, miR-122, miR-206 and miR-210, we overexpressed these miRNAs in human Hela cells by transfecting them with synthetic pre-miRNAs or a synthetic “negative” pre-miRNA as control (miR-Neg1). RNA samples were harvested at 48 hours post-transfection and 2 independent experiments were carried out.

2021-12-20 | GSE33235 | GEO

MiR-182 and miR-203 induce EMT

Project description:Expression profiling of prostate EPT1 cells transducted with two types of miRNAs (miR-182, miR-203) and RNAi clones knocking down SNAI2.

2012-04-27 | E-MTAB-1107 | biostudies-arrayexpress

miR-206 modulates the pathogenesis of muscular dystrophy of mdx mice

Project description:In response to skeletal muscle injury, adult myogenic stem cells, known as satellite cells, are activated and undergo proliferation and differentiation to regenerate new muscle fibers. The skeletal muscle-specific microRNA, miR-206, is up-regulated in satellite cells following muscle injury, but its role in muscle regeneration has not been defined. Here we show that skeletal muscle regeneration in response to cardiotoxin injury is impaired in mice lacking miR-206. Loss of miR-206 also accelerates and exacerbates the dystrophic phenotype of mdx mice, a model for Duchenne muscular dystrophy. MiR-206 promotes satellite cell differentiation and fusion to form multinucleated myofibers by suppressing a collection of negative regulators of myogenesis. Our findings reveal an essential role for miR-206 in satellite cell differentiation during skeletal muscle regeneration and as a modulator of Duchenne muscular dystrophy.

2012-05-01 | GSE36077 | GEO

miR-206 modulates the pathogenesis of muscular dystrophy of mdx mice

2012-04-30 | E-GEOD-36077 | biostudies-arrayexpress

miR-206 pulldowns in FAPs to idenfity transcript targets

Project description:Biotin labelled miR-206 mimics ('06") and miR-Control mimics ("NC") were used to indentify putative miRNA transcript targets in FAPs form skeletal muscle

2021-05-01 | GSE171504 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data